DSP p.(Thr2104Glnfs*12) variant presents variably with early onset severe arrhythmias and left ventricular cardiomyopathy by Heliö, Krista et al.
RESEARCH ARTICLE Open Access
DSP p.(Thr2104Glnfs*12) variant presents
variably with early onset severe
arrhythmias and left ventricular
cardiomyopathy
Krista Heliö1* , Tiia Kangas-Kontio2, Sini Weckström1, Sari U. M. Vanninen3, Katriina Aalto-Setälä3,4,
Tero-Pekka Alastalo2, Samuel Myllykangas2, Tiina M. Heliö1† and Juha W. Koskenvuo2†
Abstract
Background: Dilated cardiomyopathy (DCM) is a condition characterized by dilatation and systolic dysfunction of
the left ventricle in the absence of severe coronary artery disease or abnormal loading conditions. Mutations in the
titin (TTN) and lamin A/C (LMNA) genes are the two most significant contributors in familial DCM. Previously
mutations in the desmoplakin (DSP) gene have been associated with arrhythmogenic right ventricular
cardiomyopathy (ARVC) and more recently with DCM.
Methods: We describe the cardiac phenotype related to a DSP mutation which was identified in ten unrelated
Finnish index patients using next-generation sequencing. Sanger sequencing was used to verify the presence of
this DSP variant in the probands’ relatives. Medical records were obtained, and clinical evaluation was performed.
Results: We identified DSP c.6310delA, p.(Thr2104Glnfs*12) variant in 17 individuals of which 11 (65%) fulfilled the
DCM diagnostic criteria. This pathogenic variant presented with left ventricular dilatation, dysfunction and major
ventricular arrhythmias. Two patients showed late gadolinium enhancement (LGE) and myocardial edema on
cardiac magnetic resonance imaging (MRI) that may suggest inflammatory process at myocardium.
Conclusions: The patients diagnosed with DCM showed an arrhythmogenic phenotype as well as SCD at young
age supporting the recently proposed concept of arrhythmogenic cardiomyopathy. This study also demonstrates
relatively low penetrance of truncating DSP variant in the probands’ family members by the age of 40. Further
studies are needed to elucidate the possible relations between myocardial inflammation and pathogenic DSP
variants.
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Background
Dilated cardiomyopathy (DCM) is characterized by left
ventricular systolic dysfunction and dilatation of left
ventricle in the absence of severe coronary artery disease
or abnormal loading conditions such as hypertension or
valvular disease [1]. Diagnosis is traditionally made by
cardiac imaging, usually echocardiography. DCM is
typically an adult-onset disease, but disease onset may
take place already in infancy [2]. There is a wide variabil-
ity in phenotypic expression and severity as clinical pres-
entation varies from asymptomatic to end-stage heart
failure or even sudden cardiac death (SCD) [2]. The
prevalence of DCM in the general population is still
unknown and it has previously been estimated to be 1:
2500–1:3000 [3, 4]. These figures, however, are based on
old data and the prevalence is now estimated to be much
higher [5].
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Familial DCM is typically considered to be a mono-
genic disorder and most commonly autosomal dominant
inheritance has been reported [1, 2, 6, 7]. However, X-
linked, recessive and mitochondrial inheritance patterns
have been observed [6]. As much as 30–50% of DCM is
thought to be genetic or familial [6, 8]. Over 40 genes
have been related to DCM [8] and the most common
genetic cause is a truncating variant in titin gene (TTN)
[6, 9–11]. Mutations of lamin A/C gene (LMNA) are the
second most common cause of DCM, causing 5–8% of
familial DCM [12]. The most common causative genes
in order of prevalence are TTN, LMNA, DSP, MYH7
(beta-myosin heavy chain), RBM20 (RNA binding motif
protein 20), TNNT2 (Troponin 2), TPM1 (tropomyosin
1), FLNC (filamin C) and DES (desmin) [13, 14]. Muta-
tions in sarcomeric proteins have some overlap to HCM
[6]. Various genes coding cytoskeleton proteins such as
DSC2 (desmocollin-2) and DSG2 (desmoglein 2) have
also been associated with DCM and arrhythmogenic
right ventricular cardiomyopathy (ARVC) [6].
DSP codes for the protein desmoplakin, which binds
intermediate filament proteins to desmosomal plaques
and is thus an essential part of a functional desmosome
[15, 16]. Desmosomes are intercellular junctions that
provide mechanical strength to tissues undergoing phys-
ical stress [15].
Earlier mutations in the DSP gene have mostly been
associated with ARVC, which is an inherited cardiac
disorder affecting usually the right ventricle [17–19].
The disorder is characterized by fibrofatty replacement,
abnormal contraction and dilatation of the right ven-
tricle (RV) [17, 20]. Ventricular arrhythmias often occur
and may even lead to sudden cardiac death, especially in
young people and athletes [20]. The diagnosis is based
on the rather complex revised 2010 Task Force Criteria,
and is a combination of major and minor criteria from
different areas including RV function and structure, elec-
trocardiogram (ECG) findings as well as genetic or
familial background [21].
Previously the classification of cardiomyopathies has
been based mainly on cardiac imaging or complex cri-
teria, as for ARVC. More recently it has been observed
that some phenotypes do not fit these earlier classifica-
tions. The concept of arrhythmogenic cardiomyopathy
(ACM) has also been proposed, however, there are no
diagnostic criteria for it so far. ACM comprises a group
of cardiomyopathies with ventricular arrhythmias and
right and/or left ventricular affection.
We found this DSP c.6310delA, p.(Thr2104Glnfs*12)
variant interesting because it was found in a previous
study in six patients who were diagnosed with DCM
[13]. In this study we describe the cardiac phenotype re-
lated to this DSP variant in ten Finnish index patients
and their family members.
Methods
Subjects
The study included ten index patients with the DSP vari-
ant c.6310delA, p.(Thr2104Glnfs*12), of which six
participated earlier Finn-DCM study [13] and were re-
cruited from Helsinki University Hospital and four were
recruited from Tampere University Hospital. To better
understand the manifestation of this DSP variant in the
families, all the available family members were exam-
ined. All the participants gave written informed consent,
and the study was approved by the Ethical Review Com-
mittee of The Department of Medicine, University of
Helsinki (HYKS 26/99, HYKS 16/99, HYKS 17/99,
HYKS 19/2000, HYKS 8/2000, Dnro 307/13/03/01/2011,
TMK11§274,16.12.2015). We have the permission from
Statistics Finland and Ministry of Social Affairs and
Health to obtain clinical data from deceased patients for
research purposes.
The probands with DCM were diagnosed with the
following criteria: left ventricular end-diastolic diameter
(LVEDD) > 27mm/m2 and left ventricular systolic dys-
function (Left ventricular ejection fraction < 45%) in the
absence of significant coronary artery disease or abnor-
mal loading conditions such as hypertension or valvular
disease. The relatives were also considered to be possibly
affected if they had one or more of the following clinical
abnormalities: conduction defects, atrial fibrillation (at
age of < 50 years), sinus node dysfunction and dilatation
or impaired systolic function of the left ventricle.
Family history was obtained, and pedigrees were
drawn. All the available hospital records of the partici-
pants were acquired, and clinical data were collected
from these records. Some of the patients were evaluated
as part of this study by physical examination, 12-lead
ECG, echocardiography and appropriate laboratory tests
at the Heart and Lung Center in Helsinki. Cardiac mag-
netic resonance imaging (MRI), Holter, angiography and
myocardial biopsy were performed in some cases. All
participants of this study are of Finnish ethnicity.
Molecular genetic studies
The genetic testing was carried out at the Blueprint
Genetics laboratory at Helsinki, Finland. Eight index pa-
tients were tested using the Blueprint Genetics Pan Car-
diomyopathy Panel covering 101 genes associated with
cardiomyopathies and other large NGS panels including
72 and 133 genes were each used for one patient. The
presence of the DSP variant in the probands’ family
members was studied by using bi-directional Sanger
sequencing.
Mutation nomenclature is based on GenBank acces-
sion NM_004415.2 (DSP) with nucleotide one being the
first nucleotide of the translation initiation codon ATG.
The pathogenicity of this DSP variant was evaluated
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based on the American College of Medical Genetics and
Genomics (ACMG) classification scheme [22].
Results
Genetic studies
A heterozygous DSP c.6310delA, p.(Thr2104Glnfs*12)
variant was observed in ten Finnish probands with car-
diomyopathy. This variant causes a frameshift leading to
a premature stop codon at residue 12 in a new reading
frame. Thus, it is predicted to cause loss of normal pro-
tein function either through protein truncation (2114
out of 2871 aa) or nonsense-mediated mRNA decay
from the other allele. It affects both RefSeq transcripts
of DSP. There are 13 individuals heterozygous for this
variant in the Genome Aggregation Database (gnomAD,
n > 120,000 exomes and > 15,000 genomes). Of the het-
erozygotes, 11 are from the Finnish European cohort.
Database curators have made every effort to exclude
individuals with severe pediatric diseases from these co-
horts. Altogether the variant was detected in 17 individ-
uals of which 11 (65%) fulfilled DCM diagnostic criteria
and 1/17 (6%) had a slightly dilated ventricle (118.8% of
the estimated LVEDD using the Henry’s formula [23]).
In two families the variant was observed only in the
proband (Families 1 and 5, Fig. 1) and in four families
(Families 6, 8, 9 and 11, Table 1) only the proband par-
ticipated in the study. Pedigrees of the families (1-3 and
5-7) are shown in Fig. 1.
The main clinical features of the index patients and
their relatives are presented in Table 1. These features
include left ventricle end-diastolic diameter and
ejection fraction, arrhythmias and conduction defects.
Pacemaker or implantable cardioverter-defibrillator
(ICD) was implanted in 3/17 (18%) of the heterozygotes
and atrial fibrillation was observed in 4/17 (24%) and
ventricular tachycardia or ventricular fibrillation in 5/
17 (29%) of the cases. Four out of five DCM patients
with severe arrhythmia episode (VT/VF) had cardiomyop-
athy changes prior or when first time presenting with
arrhythmia episode. From one patient this information
was not available. Conduction abnormalities were present
in all but two of the families and atrioventricular-block
(AV-block) of some degree was observed in 7/17 (41%) of
the heterozygotes. Two out of 17 (12%) carriers of the
DSP mutation had a heart transplantation and the other
one also carried a heterozygous pathogenic TTN variant.
Nine patients underwent cardiac MRI and seven of
them were carriers of the DSP variant. Of these seven,
three fulfilled DCM diagnostic criteria, two had LGE as
well as cardiac edema, one had only LGE. Fibrofatty
replacement was not identified in any of the patients.
Two out of seven genotype positive family members
had DCM at ages 57 and 60, one had dilated LV with
normal EF at age 56, one had second degree AV block at
age 43 and three others were considered as genotype
positive yet phenotype negative at ages 40, 49 and 53.
All genotype negative family members were unaffected.
Based on the variant classification scheme that
follows the ACMG guidelines, this DSP c.6310delA,
p.(Thr2104Glnfs*12) variant can be considered as
pathogenic.
Family 1
Proband (II.5) of this family was diagnosed with DCM at
the age of 51. His BNP (b-type natriuretic peptide) con-
centration was 2135 ng/l at its highest. He had no his-
tory of arrhythmias, but ECG showed left anterior
hemiblock. On echocardiography his LVEDD was 80
mm and LVEF 10–15%. The proband later received a
heart transplant. Myocardial biopsy was taken, and no
amyloidosis was observed. In addition to the DSP
variant, the proband also had a pathogenic variant, TTN
c.100230_100234delinsGACA, p.(Val33411Thrfs*32); N
M_001267550.1. The same TTN deletion, but not the
DSP variant, was also found in two other members of
the family, the proband’s brother (II.4) and nephew
(III.7) who both were affected.
Family 2
Proband (II.2) of this family was a 67-year-old female di-
agnosed with DCM at the age of 46. The patient had
suffered from atrial fibrillation and ECG showed right
bundle branch block as well as left anterior hemiblock.
Her pro-BNP (pro b-type natriuretic peptide) concentra-
tion was 650 ng/l and on echocardiography her LVEDD
was 68mm and LVEF 35%. The proband died at the age
of 69 suddenly. In autopsy both cardiac ventricles were
enlarged, there was no significant coronary artery dis-
ease, neither signs of myocardial infarct nor pulmonary
embolism. The cause of death was considered to be car-
diac. Proband’s genotype positive sister (II.4) was diag-
nosed with DCM at the age of 60. She has no
arrhythmias, but ECG showed 1-degree AV block and
left anterior hemiblock. On echocardiography her
LVEDD was 55 mm and LVEF 45%. Her pro-BNP
concentration was 1742 ng/l at its highest. Proband’s 49-
year-old genotype positive daughter (III.2) had normal
findings in cardiac evaluations. At first cardiac evalu-
ation proband’s genotype positive 40-year-old nephew
(III.6) had normal findings. One year later a cardiac MRI
was performed and his LVEDV (Left Ventricular End-
Diastolic Volume) was 182 ml, LVEF 54%, RVEDV
(Right Ventricular End-Diastolic Volume) 173 ml and
RVEF (right ventricular ejection fraction) 56%. There
was considerable acute edema in the basal and mid-third
anterolateral left ventricle as well as subepicardial inten-
sive late gadolinium enhancement (LGE) within the
same area.
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Fig. 1 Pedigrees of six families affected with the DSP c.6310delA, p.(Thr2104Glnfs*12) variant. Squares represent men and circles women. Black-
filled symbols represent individuals who fulfill DCM diagnostic criteria. Grey symbol represents individual who was considered affected. Arrows
indicate index patients. Carriers of the DSP p.(Thr2104Glnfs*12) variant are marked in symbols with bolded outlines. Genotypes: +/− heterozygous
for the DSP p.(Thr2104Glnfs*12), −/− wild type allele, * TTN p.(Val33411Thrfs*32). Year of birth, left ventricular ejection fraction and end-diastolic
diameter and other clinical features listed below the symbols. LVEF left ventricular ejection fraction (%); LVEDD left ventricular end-diastolic
diameter (mm). Pacemaker/Cardiac transplant: + indicates yes, − indicates no. ECG (electrocardiogram) - SR indicates sinus rhythm; (p)L/RBBB
(partial) left/right bundle branch block; LAHB left anterior hemiblock. Arrhythmias - VT for ventricular tachycardia; VES for ventricular extrasystoles;
AF for atrial fibrillation; NA not available. ProBNP pro b-type natriuretic peptide, ** BNP b-type natriuretic peptide
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Table 1 The main clinical features of the index patients and their relatives
Family Age (M/
F)
Genotype, * =
TTN+
Conduction
defect
Arrhythmias PM,
ICD
LVEDD
(mm)
EF
(%)
proBNP (ng/l),
** = BNP
Age at
dg
Phenotype Other
Family 1
II.2 68 M −/− AVB1 no no 53 76 22 –
II.4 65 M −/−* pLBBB VT, VESm/R,
AF
ICD 68 33 2059 58 DCM
II.5 51 M +/− * LAHB no no 80 10–
15
2135** 51 DCM Heart
transplant
II.9 63 M −/− no no no 47 65 13 –
III.1 41 M −/− no no no 48 57 16 –
III.3 31 M −/− no no no 58 67 109 –
III.7 44 M −/−* LAHB no no 55 14 NA 44 DCM
Family 2
II.2 67F +/− LAHB, RBBB AF no 68 30 650 46 DCM SCD
II.4 66F +/− AVB1, LAHB no no 55 45 1742 60 DCM
III.2 49F +/− no no no 49 50–
56
43 –
III.3 47 M −/− no no no 59 57 30 –
III.4 46 M −/− no no no 54 64 55 –
III.5 42 M −/− no bradycardia no 56 55 56 –
III.6 40 M +/− no no no 52 54–
55
79 –
IV.1 26 M −/− pRBBB no no 49 54–
59
20 –
Family 3
II.1 81 M +/− AVB1, LBBB VTm, AF no 83 18–
24
23,478 72 DCM
III.1 56 M +/− no no no 60 52 265 – Slightly dilated ventricle
(Henry’s formula: 118.8%)
III.2 53 M +/− no no no 54 56–
58
13 –
III.3 49F −/− no no no 48 63 24 –
Family 5
II.3 54F +/− AVB1, LAHB VTm, VESp no 60 30–
35
1400 43 DCM
III.1 21F −/− no bradycardia no 50 60 71 –
Family 6
II.1 59 M +/− AVB3 VT, AF PM 83 19 9836 48 DCM Heart
transplant
Family 7
II.2 70F +/− AVB2, LAHB VESp, AF CRT-D 60 15–
20
2428 50 DCM
II.4 62F −/− no no no 47 72 48 –
II.5 57 M +/− no VES no 67 32 455 NA DCM
III.1 50F −/− no no no 46 65 123 –
III.3 47 M −/− NA NA no NA NA NA –
Family 8
48F +/− AVB1 VT PM 70 22 3117 42 DCM
Family 9
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Family 3
Proband (II.1) is an 81-year-old male diagnosed with
DCM at the age of 72. He has had ventricular tachycar-
dia as well as atrial fibrillation. ECG showed a first-
degree AV block and left bundle branch block. The pro-
band had very high levels of pro-BNP (23,478 ng/l) and
on echocardiography his LVEDD was 83mm and LVEF
18–24%. Proband’s both sons (III.1, III.2) were found to
be heterozygous for the DSP variant. Proband’s eldest
son (III.1) is a 56-year-old male with coronary artery dis-
ease. He has no conduction defects nor arrhythmias. On
echocardiography his LVEDD was 60mm (118.8% of the
estimated LVEDD using the Henry’s formula) and LVEF
52%. Cardiac MRI demonstrated a slightly dilated left
ventricle with impaired function and the wall-thickness
in inferolateral area was 3–4 mm locally. Proband’s other
son (III.2) is a 53-year-old male who had normal find-
ings in cardiac evaluations.
Family 5
Proband (II.3) was diagnosed with DCM at the age of
43. She suffered from ventricular tachycardia and ven-
tricular extrasystoles. On echocardiography her LVEDD
was 60mm and LVEF 30–35%, ECG showed a 1-degree
AV block and left anterior hemiblock. Cardiac MRI
demonstrated a dilated left ventricle with end-diastolic
volume of 219 ml and LVEF of 41%. Her pro-BNP con-
centration was 1400 ng/l at its highest.
Family 6
Proband (II.1) was diagnosed with DCM at the age of
48. He had high levels on pro-BNP (9836 ng/l) and on
echocardiography his LVEDD was 83mm and LVEF
19%. He had mild mitral regurgitation and later devel-
oped a 3-degree AV block. He had ventricular tachycar-
dia as well as atrial fibrillation and he later received a
pacemaker. At the age of 59 he received a heart trans-
plant. The proband was the only member of this family
to participate in the study.
Family 7
Proband (II.2) is a 70-year-old female who developed
DCM by the age of 50 years. ECG showed 2-degree AV
block and left anterior hemiblock. She suffers from ven-
tricular extrasystoles and atrial fibrillation. She has later
received a CRT-D pacemaker. On echocardiography her
LVEDD was 60mm and LVEF 15–20%. Her pro-BNP
concentration was 2428 ng/l at its highest. Proband’s
genotype positive brother (II.5) is a 57-year-old male.
ECG showed no conduction defects, but he has had ven-
tricular extrasystoles. On echocardiography his LVEDD
was 67 mm and LVEF 32%. His pro-BNP concentration
was 455 ng/l. Proband’s son (III.2) died in car accident.
Family 8
Proband is a 48-year-old female, diagnosed with DCM at
the age of 42. She has suffered from ventricular tachy-
cardia and ECG showed a 1-degree AV block. She has
later received a pacemaker. Echocardiography showed
mild mitral regurgitation and her LVEF was 22% and
LVEDD 70mm. Cardiac MRI demonstrated a dilated left
ventricle, LVEF of 20%, reduced wall-thickness and no
fibrosis. Her pro-BNP was 3117 ng/l at its highest. The
proband was the only member of the family to partici-
pate in the study.
Family 9
Proband is a 27-year-old female who was diagnosed with
DCM at the age of 22. ECG showed no conduction de-
fects, but she has suffered from ventricular extrasystoles.
On echocardiography her LVEDD was 60 mm and LVEF
40%. At its highest her pro-BNP concentration was 400
Table 1 The main clinical features of the index patients and their relatives (Continued)
Family Age (M/
F)
Genotype, * =
TTN+
Conduction
defect
Arrhythmias PM,
ICD
LVEDD
(mm)
EF
(%)
proBNP (ng/l),
** = BNP
Age at
dg
Phenotype Other
27F +/− no VES no 60 40 400 22 DCM
Family 10
II.1 M +/− no VES no 54 52 21 –
III.1 14 M +/− no VF no 55 17 NA 14 DCM SCD
Family 11
43 M +/− AVB2 no no 52 52 20** –
Index patients are marked in bold. Symbols and abbreviations: Age (M/F) age and gender (M: male, F: female); genotype +/− heterozygous for the DSP
p.(Thr2104Glnfs*12), −/− wild type allele, * TTN p.(Val33411Thrfs*32); NA not available; AVB1–3 atrioventricular blocks type 1–3, (p)L/RBBB (partial)left/right bundle
branch block; LAHB left anterior hemiblock; Arrhythmias - VT for ventricular tachycardia: VT means VT episode without information on QRS-axis or morphology,
VTm monomorphic VT and VTp polymorphic VT; VES for ventricular extrasystoles: VES, when no information on VES morphology is available, VESm/R means that
most of the VES were monomorphic with RV origin (LBBB-morphology) and VESp when most of the VES were polymorphic; AF for atrial fibrillation; VF for
ventricular fibrillation; PM pacemaker; ICD implantable cardioverter-defibrillator; CRT-D cardiac resynchronization therapy device; LVEDD left ventricular end-
diastolic diameter (mm); LVEF left ventricular ejection fraction (%); ProBNP pro b-type natriuretic peptide, ** BNP b-type natriuretic peptide; Age at dg - age at
diagnosis of cardiomyopathy; Phenotype - phenotype at diagnosis; DCM dilated cardiomyopathy; Other – other significant clinical features; SCD sudden
cardiac death
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ng/l. Cardiac MRI demonstrated an increase in signal
intensity on the lateral wall of the left ventricle and there
was also patchy LGE on the lateral left ventricular wall
subepicardially and on the right ventricle side of the
septum. Also, slightly elevated Troponin T (TnT)
concentrations were observed (TnT 18–39 ng/l, normal
range < 14 ng/l). Endomyocardial biopsy was taken 6
months later and it showed variation in nucleolar shape
and size and myodegeneration but no sign of myocardi-
tis. The proband was the only member of this family to
participate in the study.
Family 10
Proband (III.1) was an apparently healthy 14-year-old
male, who had ventricular fibrillation while watching TV
at home. He was resuscitated but succumbed 2 days
later at the hospital. At the hospital ECG showed no
conduction defects, and on echocardiography his LVEF
was 17% and LVEDD 55mm. No known Long QT Syn-
drome (LQTS) causing variants were found on genetic
evaluation. On autopsy, histology did not demonstrate
findings compatible with acute myocarditis. There were
no signs of amyloidosis or hemochromatosis. Plakoglo-
bin staining was normal. Interstitial fibrosis of varying
grades could be observed. Proband’s genotype positive
father (II.1) has had ventricular extrasystoles whereas
ECG showed no conduction defects. His pro-BNP con-
centration was 21 ng/l and on echocardiography his
LVEDD was 54 mm (111% of the estimated LVEDD
using the Henry’s formula) and LVEF 52%. Cardiac MRI
demonstrated no clear LGE.
Family 11
Proband is a 43-year-old male with a 2-degree AV-
block. Cardiac MRI demonstrated slightly dilated ventri-
cles and atriums, LVEF was 58% and RVEF 60%. There
was no edema. Linear and midmyocardial LGE compat-
ible with fibrosis was observed. Proband was the only
member of the family that could be recruited to this
study and we have no knowledge of proband’s parents’
genotypes, but we do know the following considering
their cause of death. Proband’s mother died suddenly at
the age of 24 while pulling a sled on the street. During
the 4 years that preceded her death, she had suffered
from palpitations of unknown cause and she had visited
the hospital several times because of chest pains. On the
last of these visits, a 1-degree AV-block was observed.
Proband’s father had alcoholic liver cirrhosis and he died
suddenly at later age due to intoxication.
Discussion
We have identified the DSP c.6310delA,
p.(Thr2104Glnfs*12) in ten Finnish index patients with
DCM. This study also demonstrates relatively low
penetrance of truncating DSP variant in the probands’
family members before age of 40 but phenotype became
evident in about half of the family members by age 60.
In addition to the previous FinnDCM study [13], this
variant has previously been reported twice in literature,
however, in both cases the patients were also carriers of
another DSP gene mutation. In both cases the phenotype
was cardio-cutaneous and in the other case, the patient
suffered sudden cardiac death [24, 25].
Nine of the index patients and two relatives fulfilled
the diagnostic criteria for DCM but at least one of the
subjects, a young previously healthy individual, had ven-
tricular fibrillation and SCD as the first manifestation of
the disease. The age of diagnosis varied greatly as the
youngest was 14 years old while the oldest participant
was 72 years old when the diagnosis was made. Two of
the participants presented edema on cardiac MRI. From
one of these patients TnT was measured and initially
elevated, then normalized in follow-up. The findings
were suggestive of some kind of inflammatory process.
The inflammatory process in the myocardium could ex-
plain some of the sudden arrhythmias as the disease
might process periodically rather than continuously.
However further studies are needed to elucidate the pos-
sible relations between DSP pathogenic variants and
myocardial inflammation.
The major findings in our subjects are ventricular
arrhythmias and dilatation of the left ventricle. Three of
the patients died suddenly and two of them at young
age. Our findings confirm the significance of DSP gene
as a cause of arrhythmogenic cardiomyopathy.
Even though some of the patients do meet the DCM
diagnostic criteria, it seems that the arrhythmogenic side
of this phenotype is more important in practice, because
the deaths were caused by arrhythmogenic events rather
than ventricular dysfunction.
Desmoplakin is coded by the DSP gene on chromo-
some 6p24.3, and there are two isoforms produced by
alternative splicing. Desmoplakin is a crucial part of
forming functional desmosomes as it interacts with
intermediate filaments and binds them to desmosomal
plaques [15, 16]. Desmosomes are intercellular junctions
that are abundant in tissues undergoing constant phys-
ical stress, such as the heart and the epidermis [15]. To
adapt to their mechanical environment, cardiomyocytes
may use different proteins such as integrins or strain-
activated ion channels [26]. The mechanical stresses the
cell experiences can be transmitted through the cyto-
skeleton to the nucleus by actin, intermediate filaments
and microtubules [26]. The main intermediate filaments
in cardiac myocytes are desmins which are connected to
desmosomes. A recent study has suggested that the
junction between intermediate filaments and desmo-
somes is specialized to endure external mechanical stress
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and having a stress absorbing function [27]. Desmo-
plakin carries a significant role in this as under most
conditions it does not experience significant tension, but
it is capable of sensing the exposure to external mechan-
ical stresses and reacting to it [27].
Mutations in DSP manifest in the skin, hair and heart
in humans. The participants in this study were not stud-
ied systematically for skin or hair abnormalities, but
there were no mentions of these kinds of defects in the
patient records. Autosomal recessively inherited muta-
tions have previously been associated with severe
disorders such as Carvajal syndrome [28–30], skin
fragility-woolly hair syndrome and lethal acantholytic
epidermolysis bullosa [31]. Autosomal dominant muta-
tions in DSP have been associated with ARVC [32],
DCM and SAM (Severe skin dermatitis, multiple aller-
gies and metabolic wasting) syndrome [33]. There are
altogether 163 truncating DSP variants reported in
ClinVar (May 2019) of which 156 (95,7%) were classified
as pathogenic or likely pathogenic. Most of the variants
classified as non-pathogenic are located in the C-
terminus.
According to gnomAD the DSP c.6310delA,
p.(Thr2104Glnfs*12) frequency in Finnish population is
0.0005081. Total allele frequency is 0.00005170. The
variant is enriched in Finnish population but the pres-
ence of this variant in the reference population could
possibly be explained by the variant’s low penetrance be-
fore the age of 40. Because of the late expression of the
phenotype, this could lead to the inclusion of variant
carriers in the reference population, who have not yet
developed the disease.
According to the 2008 position statement of the
European Society of Cardiology, cardiomyopathies have
been divided into groups based on the phenotypes and
each phenotype is divided into familial and non-familial
forms [1]. DCM is defined by dilatation and systolic
dysfunction of the left ventricle when no abnormal
loading conditions or coronary artery disease are ob-
served [1]. Right ventricular dilatation and dysfunction
may also be observed although it is not necessary for
the diagnosis.
Arrhythmogenic right ventricular cardiomyopathy is a
myocardial disorder defined by the dysfunction of the
right ventricle and the left ventricle may also be affected.
Histologically ARVC is characterized by fibrofatty re-
placement of the myocardium, abnormal contraction
and dilatation of the right ventricle. The diagnosis is
based on the latest revised Task Force diagnostic criteria,
that was published in 2010 [21]. Mutations in desmo-
somal genes, such as PKP2 (plakophilin 2), DSP, DSG2
and DSC2, have been associated with ARVC [18]. The
2008 Task Force ARVC diagnostic criteria does not take
in to account the presence of left ventricular
dysfunction. The 2010 criteria also include the biventri-
cular and LV subtypes, but there are no specific diagnos-
tic criteria for the non-classical disease patterns [21].
Not all of our participants had their right ventricles
systematically evaluated, but no abnormalities in the size
or function of the right ventricle on echocardiography
were reported in hospital records. Those who had car-
diac MRI performed, did not show any defects in the
function nor structure of the right ventricles.
This is in line with some previous studies, in which it
has been noted that DSP mutations seem to be associ-
ated with left dominant or biventricular form of ARVC
rather than the classical right dominant form, and DSP
mutation carriers have a higher risk of SCD when com-
pared to other mutation carriers [19, 34–36]. Especially
the truncating mutations of DSP were associated with
higher risk of developing LV dysfunction in ARVC [19].
Increasing amount of reports of clinical variants char-
acterized by left ventricular involvement which may be
parallel or greater than the RV involvement, has led to
the use of a broader term of “arrhythmogenic cardiomy-
opathy” (ACM) [20]. Arrhythmogenic cardiomyopathy is
characterized by fibrofatty replacement of the myocar-
dium and ventricular arrhythmias as well as impairment
of ventricular function. While ARVC is focused on the
impairment of the right ventricle, ACM is a broader
term and also includes biventricular and left-dominant
subtypes [20, 37]. Arrhythmogenic left ventricular
cardiomyopathy (ALVC) refers to a phenotype of left
ventricular cardiomyopathy with ventricular arrhyth-
mias, however, no diagnostic criteria have been estab-
lished. As the genetic background of arrhythmogenic
cardiomyopathies is gradually revealed, it will also be
possible to better characterize the related phenotypic
variation.
Conclusion
This s.6310delA DSP variant causes an arrhythmogenic
phenotype in addition to the suboptimal function of the
left ventricle although fibrofatty infiltration was not ob-
served. Our findings concur with the proposed concept
of arrhythmogenic cardiomyopathy but more research in
the subject is still needed. The variant is more common
in the Finnish population as compared to many other
populations. It might also modify the risk of ventricular
arrhythmias for example in the context of coincidental
coronary artery disease. Understanding the genetic back-
ground may have some significance in the diagnosis and
treatment of these diseases in the future.
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